Evidence map›Paper›PMID 42095251›Full record

ArticleHaematologica2026

Altered immune and treatment response gene expression signatures among povertyexposed children with B-cell acute lymphoblastic leukemia.

Amy Guillaumet-Adkins, Elnaz Mirzaei Mehrabad, Noori Sotudeh, Sayalee Potdar, Tushara Vijaykumar, Monica Nair, Valeriya Dimitrova, Julia Frede, Yana Pikman, Marian Harris and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Amy Guillaumet-AdkinsPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Harvard and MIT, Cambridge, MA.
Elnaz Mirzaei MehrabadHuntsman Cancer Institute, Salt Lake City, UT.
Noori SotudehPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Sayalee PotdarPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Tushara VijaykumarMedical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Monica NairMedical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Valeriya DimitrovaPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
Julia FredeMedical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Yana PikmanPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA.
Marian HarrisHarvard Medical School, Boston, MA, USA; Department of Pathology, Boston Children's Hospital, Boston, MA.
Andrew E PlacePediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA.
Lewis B SilvermanPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Columbia University, New York City, NY.
Jens G LohrHuntsman Cancer Institute, Salt Lake City, UT, USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA.
Kira BonaPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA. kira.bona@childrens.harvard.edu.
Birgit KnoechelPediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Huntsman Cancer Institute, Salt Lake City, UT, USA; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA. birgit.knoechel@hci.utah.edu.

Funding

Targeting oncogenic TCR signaling in PTCLP01CA233412 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2019 to 2023
$8.7M
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implicationsR01CA249185 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KNOECHEL, BIRGIT · 2021 to 2025
$1.9M
NCI NIH HHS P01 CA233412NCI NIH HHS R01 CA249185
6 · The paper itself

Abstract

Children diagnosed with cancer typically receive standardized treatment regimens. Despite highly protocolized care, children living in poverty experience a greater risk of cancer relapse and higher mortality compared to their more affluent peers1,2. Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer, and children with ALL exposed to poverty are more likely to experience early relapse3. Using single-cell RNA sequencing to analyze leukemic blasts and their microenvironment at diagnosis we found that poverty-exposed patients with standard-risk B-ALL exhibit transcriptional signatures of steroid resistance at time of diagnosis. Additionally, we observe increased expression of inflammatory signatures in myeloid cells and reduced effector signatures in CD8+ T-cells in children with B-ALL living in poverty. Further investigation of the mechanisms underlying these associations may identify opportunities for risk-adapted therapeutic strategies to improve disease outcomes in pediatric ALL.

Identifiers

PMID42095251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.